Medicine Classes A–Z

Medicine classes group medications that share similar chemical structures, mechanisms of action, or therapeutic uses. Understanding medicine classes helps healthcare providers and patients make informed decisions about medication selection, anticipate class-specific side effects, and understand why certain medicines are preferred over others in specific clinical situations.

The classification of medications is not a single universal system — multiple overlapping frameworks exist, each serving a different purpose in clinical pharmacology, drug regulation, pharmacy benefit management, and patient education. Understanding these systems helps explain why the same drug may be classified differently depending on the context.

The ATC Classification System

The Anatomical Therapeutic Chemical (ATC) classification system, maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology, is the most widely used international drug classification framework. It organizes medicines into five hierarchical levels:

• Level 1 — Anatomical main group: The organ system or body part the drug primarily acts upon (e.g., A = Alimentary tract and metabolism, C = Cardiovascular system, N = Nervous system)
• Level 2 — Therapeutic main group: The therapeutic use within that anatomical group (e.g., C09 = Agents acting on the renin-angiotensin system)
• Level 3 — Therapeutic/pharmacological subgroup: More specific therapeutic or pharmacological classification (e.g., C09A = ACE inhibitors)
• Level 4 — Chemical/therapeutic/pharmacological subgroup: Chemical class within the group (e.g., C09AA = ACE inhibitors, plain)
• Level 5 — Chemical substance: The individual drug entity (e.g., C09AA05 = Ramipril)

The ATC system enables standardized drug utilization research, pharmacoepidemiological studies, and international comparisons of prescribing patterns. Every approved drug in WHO member states receives an ATC code, making it the closest thing to a universal pharmaceutical classification language.

Pharmacological Classification

Pharmacological classification groups drugs by their mechanism of action — what they do at the molecular or cellular level. This is the most scientifically precise classification approach and the one most directly relevant to understanding drug effects, predicting interactions, and anticipating toxicities.

For example, within the broad category of antihypertensives, pharmacological classification distinguishes between:

• ACE inhibitors (angiotensin-converting enzyme inhibition → reduced angiotensin II → vasodilation)
• ARBs (direct AT1 receptor blockade → same downstream effect via different mechanism)
• Beta blockers (beta-adrenergic receptor blockade → reduced heart rate and cardiac output)
• Calcium channel blockers (L-type calcium channel blockade → reduced smooth muscle contraction)
• Thiazide diuretics (Na-Cl cotransporter inhibition → reduced plasma volume)

All of these lower blood pressure, but through fundamentally different mechanisms — which is why they have different secondary indications, different contraindications, different interaction profiles, and different patient-specific advantages. Pharmacological classification makes these distinctions explicit.

Chemical Classification

Chemical classification groups drugs by their molecular structure. This is particularly relevant for understanding cross-reactivity and allergies. Penicillin allergy, for instance, raises questions about cross-reactivity with cephalosporins — both share a beta-lactam ring structure, though the actual clinical cross-reactivity is much lower than historically believed (approximately 1-2% for true IgE-mediated reactions).

Chemical classification also helps explain why drugs within a class may have meaningfully different properties. Beta blockers, for example, are classified by their structural selectivity: cardioselective agents (metoprolol, atenolol, bisoprolol) preferentially block beta-1 receptors in cardiac tissue, while non-selective agents (propranolol, carvedilol) block both beta-1 and beta-2 receptors — making non-selective agents more likely to cause bronchospasm in asthmatic patients.

Therapeutic Classification

Therapeutic classification organizes drugs by the condition they treat, regardless of mechanism. This is the classification system most familiar to patients and the one used by most pharmacy benefit managers when building drug formularies. Antidiabetic medications, antihypertensives, antidepressants, and antibiotics are all therapeutic categories.

The limitation of pure therapeutic classification is that the same drug may treat multiple conditions via the same or different mechanisms. GLP-1 receptor agonists (semaglutide, liraglutide) are classified as antidiabetics, but are increasingly used for obesity management and show cardiovascular protective effects that extend beyond blood glucose control. SGLT2 inhibitors similarly span diabetes, heart failure, and chronic kidney disease treatment — a single mechanism producing therapeutic benefits across multiple organ systems.

Understanding medicine classes is not merely an academic exercise. Class-level knowledge directly informs clinical decision-making in several critical ways:

Shared Mechanisms Predict Shared Effects

When you understand how a medicine class works, you can predict the therapeutic effects, side effects, and contraindications for any member of that class — even medicines you have never encountered before. All HMG-CoA reductase inhibitors (statins) will lower LDL cholesterol. All COX inhibitors (NSAIDs) will reduce prostaglandin synthesis — producing anti-inflammatory, analgesic, and antipyretic effects, but also potentially compromising renal prostaglandin synthesis and gastrointestinal mucosal protection.

This principle extends to drug toxicity. All aminoglycoside antibiotics carry nephrotoxicity and ototoxicity risk, regardless of which specific aminoglycoside is used. All fluoroquinolones carry risk of tendon rupture (FDA black box warning), QTc prolongation, and — recognized in 2016 — the risk of potentially disabling and irreversible adverse effects involving tendons, muscles, joints, nerves, and the central nervous system. These are class effects: knowing the class predicts the risk.

Class Effects Enable Therapeutic Alternatives

When a patient cannot tolerate one medicine in a class, another member of the same class may be better tolerated due to subtle differences in receptor selectivity, pharmacokinetic properties, or metabolic pathway. ACE inhibitors cause a persistent dry cough in approximately 10-20% of patients (due to bradykinin accumulation from ACE inhibition). ARBs produce the same antihypertensive effect via AT1 receptor blockade — without affecting ACE, and therefore without the bradykinin-mediated cough. Switching from an ACE inhibitor to an ARB is one of the most common class-based therapeutic alternatives in clinical practice.

Similarly, SSRIs differ in their pharmacokinetic profiles and CYP enzyme interactions. Fluoxetine is a potent CYP2D6 inhibitor with a very long half-life (days to weeks for the active metabolite norfluoxetine), making it unsuitable for patients on CYP2D6-metabolized medications or those who need rapid washout. Escitalopram has minimal CYP enzyme interactions, making it one of the most widely used SSRIs in polypharmacy situations. Understanding SSRI class properties — and individual member differences — informs appropriate selection.

Class-Based Drug Interactions

Many critical drug interactions are class-based rather than drug-specific. Understanding the metabolic pathway of a medicine class predicts interactions for all members of that class:

• Statins and CYP3A4 inhibitors: Most statins (lovastatin, simvastatin, atorvastatin) are metabolized by CYP3A4. Potent CYP3A4 inhibitors — clarithromycin, itraconazole, HIV protease inhibitors — dramatically increase statin blood levels, raising the risk of myopathy and rhabdomyolysis. This is a class interaction: any CYP3A4 inhibitor combined with CYP3A4-metabolized statins raises the risk.
• Benzodiazepines and CNS depressants: All benzodiazepines produce CNS depression via GABA-A potentiation. Combining any benzodiazepine with opioids, alcohol, or other CNS depressants produces additive CNS depression with risk of respiratory failure — a class interaction that has driven multiple black box warnings and FDA safety communications.
• QTc prolongation: Multiple medicine classes carry QTc prolongation risk: class IA/IC/III antiarrhythmics, certain antipsychotics (haloperidol, quetiapine), some antibiotics (fluoroquinolones, azithromycin), antiemetics (ondansetron, domperidone), and methadone. Combining drugs from multiple QTc-prolonging classes multiplies the risk of torsades de pointes.
• Serotonin syndrome: Any combination of drugs that increase serotonergic activity — SSRIs, SNRIs, MAOIs, triptans, tramadol, linezolid, methylene blue, St. John's Wort, certain opioids (meperidine, tapentadol) — risks serotonin syndrome. This is a mechanism-based class interaction, not specific to any individual drug combination.

Class Effects Inform Contraindications

Some contraindications apply to entire medicine classes, not just specific drugs. Beta blockers as a class are contraindicated in severe bradycardia, high-degree AV block, and decompensated heart failure with low cardiac output — because all beta blockers reduce heart rate and cardiac contractility. The class contraindication in reactive airway disease applies most strongly to non-selective beta blockers, less so to cardioselective agents at low doses.

ACE inhibitors and ARBs share a class contraindication in pregnancy (risk of fetal renal damage, oligohydramnios, skull hypoplasia in second and third trimesters — FDA Pregnancy Category D). This applies to all members of both classes, not specific drugs. NSAIDs share a class contraindication in the third trimester of pregnancy due to risk of premature closure of the ductus arteriosus.

Cardiovascular Medicine Classes

Cardiovascular pharmacology encompasses some of the most widely prescribed medicine classes in clinical practice. An estimated 1 in 3 American adults has hypertension, and cardiovascular disease remains the leading cause of death in the United States — making this class category central to primary care pharmacotherapy.

The renin-angiotensin-aldosterone system (RAAS) is targeted by two major classes: ACE inhibitors (lisinopril, enalapril, ramipril) and ARBs (losartan, valsartan, irbesartan). Both reduce the vasoconstrictive effects of angiotensin II, lower blood pressure, reduce proteinuria in chronic kidney disease, and improve outcomes in heart failure. RAAS blockade provides renal protection in diabetic nephropathy and is a guideline-recommended treatment for heart failure with reduced ejection fraction. A third class — aldosterone antagonists (spironolactone, eplerenone) — blocks the downstream effects of aldosterone, providing additional benefit in heart failure and resistant hypertension.

Statins represent one of the most impactful medicine classes in preventive cardiology. By competitively inhibiting HMG-CoA reductase — the rate-limiting enzyme in hepatic cholesterol synthesis — statins reduce LDL cholesterol by 30-60% depending on dose and agent. Landmark trials (4S, WOSCOPS, CARE, LIPID, JUPITER) established that statin therapy reduces major cardiovascular events by approximately 25-35% per 1 mmol/L reduction in LDL-C. Beyond LDL reduction, statins have pleiotropic effects including anti-inflammatory properties, plaque stabilization, and improvements in endothelial function. High-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg) are the guideline-preferred choice for secondary prevention after acute coronary syndrome.

Beta blockers remain essential in several cardiovascular conditions despite their reassessment in uncomplicated hypertension. They are guideline-recommended for heart failure with reduced ejection fraction (carvedilol, metoprolol succinate, bisoprolol have mortality-reducing evidence), post-myocardial infarction, angina, and rate control in atrial fibrillation. Cardioselectivity (metoprolol, bisoprolol, atenolol) and additional pharmacological properties (carvedilol has alpha-1 blocking activity; nebivolol releases nitric oxide) distinguish individual class members for specific clinical situations.

Psychiatric and CNS Medicine Classes

Psychiatric pharmacology involves some of the most mechanistically complex and clinically nuanced medicine classes. Unlike many other therapeutic areas, psychiatric drug effects often emerge over weeks and the relationship between receptor pharmacology and clinical response is incompletely understood.

SSRIs are the most prescribed antidepressants globally, selected for their tolerability profile relative to older tricyclic antidepressants and monoamine oxidase inhibitors. All SSRIs block the serotonin transporter (SERT) — increasing synaptic serotonin availability — but they differ significantly in CYP enzyme interactions (fluoxetine and paroxetine are potent CYP2D6 inhibitors; citalopram, escitalopram, and sertraline have minimal CYP effects), half-life (fluoxetine's active metabolite has a half-life exceeding 7 days; paroxetine's short half-life produces discontinuation syndrome more readily), and secondary receptor effects (paroxetine has anticholinergic properties; mirtazapine blocks histamine H1 receptors causing sedation and weight gain).

Benzodiazepines produce anxiolytic, hypnotic, muscle relaxant, and anticonvulsant effects by potentiating GABA at the GABA-A receptor — specifically increasing the frequency of chloride ion channel opening. All benzodiazepines share the risk of tolerance, physical dependence, and withdrawal (potentially life-threatening with abrupt cessation after prolonged use). The class is differentiated by half-life: short-acting agents (triazolam, oxazepam) have different clinical roles than long-acting agents (diazepam, clonazepam). Lorazepam, midazolam, and diazepam — all benzodiazepines — are used in acute seizure management, procedural sedation, and alcohol withdrawal, selected based on onset, duration, and route of administration.

Atypical antipsychotics (second-generation antipsychotics, SGAs) represent a significant advance over first-generation agents (haloperidol, chlorpromazine) in terms of extrapyramidal side effect profile — primarily because SGAs have higher 5-HT2A relative to D2 receptor binding, which modulates dopamine release in the nigrostriatal pathway. However, SGAs introduced new metabolic concerns: weight gain (olanzapine, clozapine most pronounced), dyslipidemia, and risk of type 2 diabetes. Clozapine, the most effective antipsychotic for treatment-resistant schizophrenia, requires a REMS program due to the risk of agranulocytosis (1-2%), requiring regular absolute neutrophil count monitoring.

Anti-Infective Medicine Classes

Antimicrobial pharmacology is defined by the principle of selective toxicity: exploiting biological differences between human cells and microbial cells to kill or inhibit pathogens without harming the host. The major antibiotic target systems correspond to specific bacterial structures absent or sufficiently different in mammalian cells.

Beta-lactams — including penicillins, cephalosporins, carbapenems, and monobactams — inhibit bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs), enzymes that cross-link peptidoglycan strands in the bacterial cell wall. The beta-lactam ring is essential for antibacterial activity, and beta-lactamase enzymes (produced by many resistant organisms) hydrolyze this ring to inactivate the drug. Beta-lactamase inhibitors (clavulanate, tazobactam, sulbactam, avibactam) are combined with beta-lactams to overcome this resistance mechanism.

Fluoroquinolones inhibit bacterial topoisomerases II (DNA gyrase) and IV, enzymes required for DNA replication, transcription, and repair. They are bactericidal with concentration-dependent killing — achieving higher peak concentrations (relative to MIC) improves efficacy. Despite broad spectrum activity and good oral bioavailability, quinolone use has been restricted by the FDA and major infectious disease societies due to the serious adverse effect profile: fluoroquinolones carry black box warnings for tendinitis/tendon rupture (especially in patients over 60, on corticosteroids, or with renal/cardiac/lung transplants), peripheral neuropathy, CNS effects, and aortic aneurysm/dissection risk. Many guidelines now recommend reserving fluoroquinolones for infections with no alternatives, to preserve their utility and limit side effects.

Macrolides (azithromycin, clarithromycin, erythromycin) inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking translocation of the growing peptide chain. They have excellent tissue penetration (particularly azithromycin, which achieves intracellular concentrations many times plasma levels — enabling once-daily dosing for community-acquired pneumonia with a short 5-day course). Macrolide cardiac concerns (QTc prolongation, particularly with clarithromycin and erythromycin; azithromycin also carries some risk) and growing Streptococcus pneumoniae resistance have influenced prescribing patterns.

Metabolic and Endocrine Medicine Classes

The management of type 2 diabetes has been transformed by the development of novel pharmacological classes with mechanisms extending far beyond glucose lowering. Modern diabetes pharmacotherapy targets multiple pathways and delivers cardiovascular and renal benefits independent of glycemic control.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) mimic the incretin hormone glucagon-like peptide-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and — crucially — reducing appetite and food intake through central nervous system effects. Major cardiovascular outcome trials (LEADER for liraglutide, SUSTAIN-6 for semaglutide, REWIND for dulaglutide) demonstrated significant reductions in major adverse cardiovascular events (MACE) in high-risk patients — cardiovascular benefits that led to updated ADA guidelines recommending GLP-1 agonists as preferred second agents in type 2 diabetes patients with established cardiovascular disease. The weight loss properties of GLP-1 agonists have driven enormous growth in their use for obesity (semaglutide at obesity doses [Wegovy], tirzepatide [Zepbound] — a dual GLP-1/GIP agonist producing even greater weight loss of 20-22%).

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) block the sodium-glucose cotransporter 2 in the renal proximal tubule, promoting urinary glucose excretion (glycosuria). This mechanism is insulin-independent, making it effective even in advanced insulin deficiency. Beyond glucose lowering, SGLT2 inhibitors reduce plasma volume (osmotic diuresis), lower blood pressure, and reduce cardiac preload. EMPA-REG OUTCOME, CREDENCE, DAPA-HF, and EMPEROR-Reduced trials demonstrated that SGLT2 inhibitors reduce cardiovascular mortality, heart failure hospitalizations, and progression of chronic kidney disease — effects seen even in patients without diabetes. SGLT2 inhibitors are now guideline-recommended for heart failure with reduced ejection fraction regardless of diabetic status.

Pain and Anti-Inflammatory Medicine Classes

Pain pharmacology involves multiple medicine classes targeting different pain mechanisms. The WHO analgesic ladder — originally designed for cancer pain — provides a framework for stepwise analgesic escalation applicable to many pain conditions.

NSAIDs inhibit cyclooxygenase enzymes (COX-1 and COX-2) that convert arachidonic acid to prostaglandins. Prostaglandins sensitize pain receptors, mediate inflammation, regulate renal blood flow, maintain gastric mucosal integrity, and promote platelet aggregation. COX-2 selective inhibitors (celecoxib, meloxicam) preserve COX-1-mediated gastric protection while maintaining anti-inflammatory efficacy — but at the cost of reduced antiplatelet effect and, at least for some COX-2 selective agents, increased cardiovascular risk (the rofecoxib withdrawal in 2004 established that COX-2 selective NSAIDs carry cardiovascular risks). All NSAIDs impair renal prostaglandin synthesis, potentially causing renal vasoconstriction and acute kidney injury, particularly in patients who are volume-depleted, elderly, or have pre-existing renal disease.

Opioid analgesics act at mu, kappa, and delta opioid receptors throughout the central and peripheral nervous system. Mu receptor activation produces the primary analgesic effect but also respiratory depression, euphoria, constipation, and physical dependence. Individual opioids differ in receptor affinity, metabolic pathway (morphine: glucuronidation; codeine: CYP2D6 activation to morphine; fentanyl, oxycodone: CYP3A4), duration of action, and available formulations. The opioid epidemic has fundamentally changed opioid prescribing practices: FDA black box warnings on all opioids, mandatory Risk Evaluation and Mitigation Strategy (REMS) programs for extended-release opioids, state prescription drug monitoring programs (PDMPs), and CDC prescribing guidelines have all been implemented to reduce opioid-related harms while preserving access for patients with legitimate medical needs.

Medicine classes rarely emerge fully formed. They typically develop through successive generations of compounds, each refining selectivity, reducing off-target effects, improving pharmacokinetics, or extending the scope of clinical applications. Understanding generational evolution illuminates why older class members are being replaced and what the design principles of newer agents reflect.

Antihistamines: First vs. Second Generation

First-generation antihistamines (diphenhydramine, chlorpheniramine, promethazine) effectively block histamine H1 receptors but readily cross the blood-brain barrier, producing significant sedation and anticholinergic effects (dry mouth, urinary retention, blurred vision, cognitive impairment). Second-generation antihistamines (cetirizine, loratadine, fexofenadine) were designed with greater polarity or active efflux mechanisms at the blood-brain barrier, dramatically reducing CNS effects while maintaining peripheral H1 blockade. Fexofenadine has minimal CNS penetration and virtually no sedation at therapeutic doses. This generational advance transformed antihistamine use from sedating first-line agents to non-sedating preferred agents for allergic rhinitis and urticaria.

Antipsychotics: First vs. Second Generation

First-generation (typical) antipsychotics (haloperidol, chlorpromazine, fluphenazine) are potent dopamine D2 receptor antagonists. They effectively control positive symptoms of schizophrenia (hallucinations, delusions, disorganized thinking) but produce significant extrapyramidal side effects (EPS): akathisia (motor restlessness), drug-induced parkinsonism, acute dystonia, and — with long-term use — tardive dyskinesia (often irreversible abnormal involuntary movements). Second-generation (atypical) antipsychotics were designed with combined D2/5-HT2A antagonism — the serotonergic component modulates dopaminergic tone in the nigrostriatal pathway, reducing EPS while maintaining antipsychotic efficacy. The tradeoff was metabolic: weight gain, dyslipidemia, and hyperglycemia emerged as significant class concerns. Third-generation partial agonists (aripiprazole, brexpiprazole, cariprazine) introduced dopamine system stabilization — acting as partial agonists at D2 receptors, providing agonist activity where dopamine is low (limbic system, reducing negative symptoms) and antagonist activity where dopamine is high (mesolimbic pathway, reducing positive symptoms), with minimal metabolic liability.

Anticoagulants: From Warfarin to DOACs

Warfarin — a vitamin K antagonist — was the only oral anticoagulant option for decades after its clinical introduction in the 1950s. It remains effective but requires regular INR monitoring due to its narrow therapeutic index and extensive drug-food interactions (any food high in vitamin K affects INR). Genetic variability in CYP2C9 (warfarin metabolism) and VKORC1 (warfarin target) produces wide inter-patient dose variability. Direct oral anticoagulants (DOACs) — dabigatran (direct thrombin inhibitor), rivaroxaban, apixaban, and edoxaban (direct factor Xa inhibitors) — transformed anticoagulation by providing predictable pharmacokinetics that do not require routine monitoring, fixed dosing, fewer drug interactions, and comparable or superior efficacy/safety compared to warfarin in clinical trials. However, DOACs require dose adjustment in renal impairment (most are partially renally cleared), have different reversal agents (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors), and are not appropriate for all indications where warfarin is used (mechanical heart valves, certain antiphospholipid antibody syndrome presentations).

Diabetes: From Insulin to Targeted Metabolic Agents

The treatment of type 2 diabetes has evolved from insulin and sulfonylureas (1950s-60s) through metformin's widespread adoption (though available in Europe much earlier, FDA-approved in the US in 1994), to thiazolidinediones (1990s, with rosiglitazone and pioglitazone's cardiovascular controversy reshaping the FDA drug approval landscape for diabetes drugs — mandating cardiovascular outcome trials for all new diabetes medicines), to the incretin era (DPP-4 inhibitors, GLP-1 agonists, 2000s-2010s), to SGLT2 inhibitors (2013-present). Each generation targets a different mechanism: from direct insulin replacement, to potassium channel closure (sulfonylureas), to insulin sensitization (metformin, thiazolidinediones), to glucose-dependent insulin secretion (incretin-based therapies), to renal glucose excretion (SGLT2 inhibitors). The latest generation delivers multi-organ benefits — cardiovascular and renal protection — that go far beyond glucose lowering, representing a paradigm shift from glucose-centric to organ-protective diabetes pharmacotherapy.

Each medicine class page in this reference provides a comprehensive clinical overview including:

• Mechanism of Action: Detailed molecular target description, receptor pharmacology, and the chain from molecular effect to clinical outcome
• Member Medicines: Complete list of approved drugs in the class with generic and brand names, available formulations, and approval dates
• Class Indications: FDA-approved indications shared across class members, with guideline recommendations where relevant
• Class Side Effects: Adverse effects attributable to the shared mechanism, distinguishing class effects from individual drug-specific effects
• Class Contraindications and Warnings: Shared contraindications, black box warnings, and high-risk populations
• Pharmacokinetics: Absorption, distribution, metabolism, and elimination characteristics with key differences between class members
• Drug Interactions: Major drug-drug interactions at the class level, with mechanism explanations
• Monitoring Parameters: Laboratory and clinical monitoring recommendations for the class
• Special Populations: Dose adjustments and considerations for renal/hepatic impairment, pregnancy, lactation, pediatrics, and geriatrics
• Therapeutic Selection: How to choose between class members based on patient-specific factors

For individual drug information including specific dosing, complete prescribing information, and detailed interaction data, use the links to individual medicine pages provided within each class profile.